M-ZOLE 3 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for M-ZOLE 3 COMBINATION PACK (M-ZOLE 3 COMBINATION PACK).
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
| Metabolism | Miconazole is primarily metabolized by hepatic CYP3A4; zinc pyrithione is minimally absorbed and metabolized locally. |
| Excretion | Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20% |
| Half-life | Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment |
| Protein binding | ~99% primarily to albumin |
| Volume of Distribution | 0.6-1.2 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: ~90% |
| Onset of Action | Oral: 1-2 hours; IV: immediate |
| Duration of Action | Oral: 12-24 hours; IV: 24-48 hours, depending on dose |
| Molecular Weight | 416.13 |
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (eGFR <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B) with dose reduction to half. |
| Pediatric use | Not recommended for children under 12 years. For children ≥12 years, same adult single dose of 3 tablets. |
| Geriatric use | No specific dose adjustment needed; monitor for adverse effects due to potential age-related renal or hepatic decline. |
| 1st trimester | Avoid. Miconazole is a teratogen in animals; systemic absorption from topical use is low but risk cannot be ruled out. Use only if clearly needed. |
| 2nd trimester | Use with caution. Systemic absorption limited but fetal risk unknown. Consider alternative treatments. |
| 3rd trimester | Avoid near term due to potential for premature labor or fetal effects from high doses. Minimal absorption from topical use may be acceptable if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for M-ZOLE 3 COMBINATION PACK (M-ZOLE 3 COMBINATION PACK).
| Placental transfer | Limited data; miconazole is highly protein bound and lipophilic, which may reduce placental transfer. Animal studies show some transfer. Systemic absorption from topical use is low (2-3%), so significant transfer is unlikely. |
| Breastfeeding | Miconazole is poorly absorbed orally and systemically after topical application. Excretion into breast milk is likely minimal. However, avoid application to breast area to prevent infant ingestion. Use with caution, especially with prolonged or extensive use. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to miconazole or any componentConcurrent use with terfenadine, astemizole, cisapride, or other CYP3A4 substrates that prolong QT interval
| Precautions | For external use only; avoid contact with eyes, Discontinue if irritation or allergic reaction occurs, Do not use on open wounds or damaged skin, Not for vaginal or oral use |
| Food/Dietary | No significant food interactions. However, avoid excessive alcohol consumption as it may worsen vulvar irritation. No known dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | M-ZOLE 3 COMBINATION PACK contains miconazole (azole antifungal). Teratogenic risk: First trimester – limited human data, animal studies show no consistent teratogenicity; however, high-dose systemic azoles have been associated with miscarriage and congenital anomalies in some studies. Second and third trimesters – generally considered low risk with topical/vaginal use, as systemic absorption is minimal. Overall, avoid in first trimester unless benefit outweighs risk; use with caution in second and third trimesters. |
| Fetal Monitoring | For vaginal use: monitor for signs of local irritation, hypersensitivity, or superinfection. No specific fetal monitoring required due to minimal systemic absorption. |
| Fertility Effects | No adverse effects on fertility reported with topical/vaginal miconazole. Systemic azoles may affect hormone levels, but this is not relevant for the combination pack's route. |
| M-ZOLE 3 COMBINATION PACK contains miconazole nitrate 200 mg vaginal suppositories and topical cream for vulvar application. Administer one suppository intravaginally at bedtime for 3 consecutive nights. The cream is for external use only to relieve itching. Avoid use during menstruation; if menstruation occurs, complete the course. If symptoms persist >7 days, reevaluate for resistant organisms or alternative diagnoses like bacterial vaginosis or trichomoniasis. |
| Patient Advice | Insert one vaginal suppository deep into the vagina at bedtime for 3 nights. · Apply a thin layer of the cream to the external genital area twice daily as needed for itching. · Do not use tampons, douche, or have vaginal intercourse during treatment. · Wash hands before and after application. · If you miss a dose, insert it as soon as remembered unless it is almost time for the next dose; do not double. · Contact your doctor if symptoms worsen or do not improve after 7 days. · Do not use if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor. |